Mayne Pharma Group (Mayne Pharma Group) Cash-to-Debt : 4.23 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Mayne Pharma Group Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Mayne Pharma Group's cash to debt ratio for the quarter that ended in Dec. 2023 was 4.23.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Mayne Pharma Group could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Mayne Pharma Group's Cash-to-Debt or its related term are showing as below:

MAYNF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18 Med: 0.32 Max: 4.63
Current: 4.23

During the past 13 years, Mayne Pharma Group's highest Cash to Debt Ratio was 4.63. The lowest was 0.18. And the median was 0.32.

MAYNF's Cash-to-Debt is ranked better than
69.04% of 1053 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs MAYNF: 4.23

Mayne Pharma Group Cash-to-Debt Historical Data

The historical data trend for Mayne Pharma Group's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Mayne Pharma Group Cash-to-Debt Chart

Mayne Pharma Group Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

0.24

0.35

0.28

0.23

4.63

Mayne Pharma Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.30	0.23	2.17	4.63	4.23

Competitive Comparison of Mayne Pharma Group's Cash-to-Debt

For the Drug Manufacturers - General subindustry, Mayne Pharma Group's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mayne Pharma Group's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's Cash-to-Debt falls into.

Mayne Pharma Group Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Mayne Pharma Group's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	147.746	/	(9.683	+	22.2)
	=	4.63

Mayne Pharma Group's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	103.622	/	(2.321	+	22.16)
	=	4.23

Mayne Pharma Group (OTCPK:MAYNF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Mayne Pharma Group Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Mayne Pharma Group (Mayne Pharma Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (OTCPK:MAYNF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

HG6:Germany MYX:Australia

Address

1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106

Website

http://www.maynepharma.com

Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.